

BMJ Open Perceptions of risk and predictive testing held by the first-degree relatives of patients with rheumatoid arthritis in England, Austria and Germany: a qualitative study

Rebecca J Stack,^{1,2} Michaela Stoffer,^{3,4} Mathias Englbrecht,⁵ Erika Mosor,³ Marie Falahee,¹ Gwenda Simons,¹ Josef Smolen,³ Georg Schett,⁵ Chris D Buckley,^{1,2} Kanta Kumar,⁶ Mats Hansson,⁷ Axel Hueber,⁵ Tanja Stamm,³ Karim Raza^{1,8}

To cite: Stack RJ, Stoffer M, Englbrecht M, *et al*.

Perceptions of risk and predictive testing held by the first-degree relatives of patients with rheumatoid arthritis in England, Austria and Germany: a qualitative study. *BMJ Open* 2016;**6**: e010555. doi:10.1136/bmjopen-2015-010555

► Prepublication history for this paper is available online. To view these files please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2015-010555>).

Received 16 November 2015
Revised 18 February 2016
Accepted 20 April 2016



CrossMark

For numbered affiliations see end of article.

Correspondence to

Dr Rebecca J Stack;
rebecca.stack@ntu.ac.uk

ABSTRACT

Objectives: The family members of patients with rheumatoid arthritis (RA) are at increased risk of developing RA and are potential candidates for predictive testing. This study explored the perceptions of first-degree relatives of people with RA about being at risk of RA and engaging in predictive testing.

Methods: 34 first-degree relatives (siblings and offspring) of patients with RA from the UK, Germany and Austria participated in semistructured interviews about their perceptions of RA risk and the prospect of predictive testing. Interviews were audio-recorded, transcribed verbatim and analysed using thematic analysis.

Results: First-degree relatives were aware of their susceptibility to RA, but were unsure of the extent of their risk. When considering their future risk, some relatives were concerned about the potential impact that RA would have on their lives. Relatives were concerned that knowing their actual risk would increase their anxiety and would affect decisions about their future. Also, relatives were concerned about the levels of uncertainty associated with predictive testing. Those in favour of knowing their future risk felt that they would need additional support to understand the risk information and cope with the emotional impact of this information.

Conclusions: Identifying individuals at risk of RA may allow targeted interventions to reduce the risk and consequence of future disease; however, relatives have concerns about predictive testing and risk information. The development of strategies to quantify and communicate risk needs to take these views into account and incorporate approaches to mitigate concerns and minimise the psychological impact of risk information.

INTRODUCTION

Rheumatoid arthritis (RA) is a chronic destructive polyarthritis. It affects ~1% of the

Strengths and limitations of this study

- This study used inductive qualitative interviews to explore perceptions about risk and predictive testing in the first-degree relatives of people with rheumatoid arthritis.
- This study identified positive and negative perspectives surrounding predictive testing, and why some people at risk may not wish to be tested.
- Further research is needed to quantify the numbers of people at risk holding negative perceptions about predictive testing and to identify the behavioural implications of these beliefs.
- Communicating risk information to relatives effectively while reducing the psychological burden associated with this information should be the focus of future interventional research.

population¹ and typically manifests in the fourth and fifth decades of life.^{2–4} Delays in diagnosis and treatment of RA are common and are associated with worse outcomes.^{5–8} Recently, an increased research effort has been directed towards the ‘at-risk’ phases of RA, prior to the development of clinical signs of joint swelling, to identify those at risk of developing RA and to reduce this risk through the modification of environmental risk factors and pharmacological intervention.^{9–11}

Genetic factors contribute significantly to the risk of RA.¹² For seropositive RA, at least half of the risk is conferred by genetic risk factors;¹³ recent large genetic studies have identified over 100 susceptibility loci.^{14 15} Population-based epidemiological studies have shown that having a family history of RA increases the risk of RA by approximately



three to five times,^{16–18} with the risk being higher in first-degree relatives than second-degree relatives.¹⁷ Furthermore, a range of environmental and lifestyle risk factors including occupational exposure to pollutants,¹⁹ body mass index,²⁰ periodontitis,²¹ reproductive factors,²² smoking²³ and dietary factors^{24–26} contribute to the increased risk of developing RA. Some of these environmental risk factors may interact mechanically with genetic risk factors to increase the risk of RA,²⁷ and others may have familial associations, thus contributing to the familial aggregation of RA.^{28 29}

Individuals with genetic and environmental risk factors for RA may progress through a phase associated with the development of systemic autoimmunity (eg, the development of autoantibodies such as rheumatoid factor,^{30 31} anticitrullinated protein/peptide antibodies and anticarbamylated protein antibodies³²) before the clinical symptoms and signs of RA manifest.⁹ It remains unclear whether there are changes detectable within the synovium during the phase of autoantibody positivity prior to the development of joint swelling.^{33 34}

Together these data suggest that information related to genotype, environmental exposures and measures of autoimmunity and inflammation may be used to predict RA development in individuals who have not yet developed clinical disease. A potential target population for such testing, with a view to risk stratification and intervention to modulate risk, are the first-degree relatives of individuals with RA. Indeed, a number of ongoing prospective studies are recruiting the first-degree relatives of patients with RA to study disease mechanisms driving the switch to RA,³⁵ to develop predictive algorithms for RA and to test interventions to reduce RA risk.³⁶ While considerable research effort is thus focused on the first-degree relatives of patients with RA, and a qualitative study has gathered data relating to their views of preventive strategies,³⁷ little is known about how such individuals view issues related to their susceptibility to and risk of developing RA, and how willing they would be to be assessed and tested to have this risk quantified. The present qualitative study addresses these issues.

PROCEDURE

Eligible participants were the first-degree relatives (offspring and siblings) of people with RA. Participants were required to be at least 18 years of age and without a diagnosis of inflammatory joint disease.

Patients with RA were approached during routine secondary care clinics in Birmingham (UK), Erlangen (Germany) and Vienna (Austria) and were given a letter to pass on to a first-degree relative of their choosing inviting them to participate in an interview about risk and predictive testing for RA. Participants were recruited between October 2014 and October 2015. It was explained to patients that it was entirely at their discretion whether to pass on the invitation letter. All research participants (ie, the participating first-degree relatives) gave written informed consent prior to interview.

The semistructured interviews were guided by an interview schedule which was informed by a review of the qualitative literature exploring perceptions of risk and testing in those at risk of developing a chronic disease.^{38 39} The interviews aimed to assess personal perceptions of risk; therefore, one-to-one interviews were conducted. In addition, an international multidisciplinary team of healthcare professionals, patient research partners and researchers working on the EuroTEAM project (<http://www.team-arthritis.eu>) reviewed and redrafted the interview schedule (see **box 1** for sample questions from the final interview schedule).

One-to-one interviews were conducted at local hospitals or by telephone (for those participants who had difficulty in attending the hospital for a face-to-face interview). Interviews lasted between 30 and 90 min and were digitally audio-recorded. In the UK, participants who wanted further information about arthritis were advised to contact Arthritis Research UK, the National Rheumatoid Arthritis Society or the local hospital's Patient Advice and Liaison Service. Participants in Austria and Germany were advised to contact the local rheumatology outpatient clinic.

The interviews were transcribed verbatim. Interviews conducted in German were translated into English following transcription. Transcripts were anonymised and analysed centrally in Birmingham, UK, by RJS.

Analysis procedure

Data collection and analysis were carried out in parallel to assess when thematic saturation of major developing

Box 1 Sample interview schedule for those at risk of developing rheumatoid arthritis (RA)

- ▶ Tell me what you know about RA?
- ▶ PROMPTS: What do you think the causes of RA could be? What do you think the risks factors for RA are? Tell me about how serious you think RA is? How would you know you had RA, for example, what symptoms would you expect? What would be the impact of RA on your life? Do you think you would be able to control RA yourself? Do you think there are treatments available that would effectively treat RA?
- ▶ Do you ever worry about the possibility of developing RA in the future?
- ▶ What would you think if you were told that you could have a test that would tell you how likely you were to develop RA?
- ▶ PROMPTS: What sort of information should this test give you? When do you think would be the right time to get this information? How would you feel about the idea of having a test that would tell you your chance of developing RA in the future? In what ways do you think it would be helpful for you to know your chances of developing RA?
- ▶ What would your concerns be if you knew what your risk of developing RA was?
- ▶ What kind of tests do you think people might be able to do to work out whether or not you might develop RA (test that are available now and tests that might become available in the future)?

themes had been achieved. The data were analysed using a thematic approach⁴⁰ facilitated by NVivo (a qualitative software programme) (NVivo qualitative data analysis software; QSR International Pty Version. 8 (2008)). Transcripts were subjected to line-by-line coding by RJS. Patient research partners blind coded three transcripts to develop reliable and inclusive themes informed by multiple perspectives. Discussion of the coding framework took place between researchers and patient research partners. Coding categories that lacked concordance were discussed and absorbed into the coding framework. The initial codes were then grouped into the most noteworthy and frequently occurring categories. The core themes extracted and presented here focus on perceptions of first-degree relatives about their personal risk of RA and their views on being tested.

RESULTS

Thirty-four first-degree relatives of patients with RA participated, 24 from the UK, 3 from Germany and 7 from Austria. Six participants were siblings of a patient with RA, 26 were the adult offspring of a patient with RA and 2 participants had a sibling and a parent with RA. Participants were aged between 23 and 67 years (mean 39 years) and 26 (76%) were women (see [table 1](#) for participant characteristics). Quotations are presented in [tables 2–5](#) and are referred to in the text using ‘Q’ followed by the quotation code.

Understanding of family history and genetic factors as risk factors for RA

The first-degree relatives of people with RA understood that there was a hereditary component to RA (Q1), and often used the word ‘genetic’ to describe the cause of their increased risk (Q2). First-degree relatives (from here on referred to as ‘relatives’) recognised that they were more susceptible to developing RA than second-degree relatives (Q3). Interestingly, some felt that they were more susceptible to developing RA than other first-degree relatives because they appeared to follow other patterns of illness displayed by their relative with RA (Q4). Additional biological factors, such as being women and some environmental factors, were also described as playing a role in the development of RA (Q2 and Q5).

When considering their perceived personal susceptibility, relatives reported that there were aspects of familial risk, particularly genetic susceptibility, which they found difficult to understand. One relative felt that effectively communicating an understanding of genetic risk to the public was extremely challenging (Q6). Others felt that they needed more information about their level of risk as a relative and the specific role that genes associated with RA played in this risk (Q7).

When considering their susceptibility to RA, relatives voiced their concerns about the future, and how being at risk of developing RA was a worry for them. Those

who had considered their personal susceptibility to RA described being fearful of what they may uncover if they were to have their risk quantified. For some, the prospect of living with RA would entail great amounts of uncertainty (Q8). For many, having witnessed the impact of RA on their sibling/parent heightened the worry they felt in relation to the possibility of developing RA themselves in the future (Q9). Interestingly, a small number of relatives had experienced joint-related symptoms but had not yet sought medical advice, being fearful of the potential outcome (Q10).

Personal considerations of RA risk and communication about risk within families

Relatives discussed knowing little about RA or its risk factors, feeling that they had been ‘shielded’ or ‘protected’ from this knowledge by their sibling/parent (Q11). Also, relatives described how they rarely discussed RA within their family unit, and in some cases, the invitation to participate in this study was the first time that the opportunity to discuss RA, and its risk had emerged (Q12). For one relative, receiving the invitation to take part in this study facilitated the first conversation he had had with his father about RA (Q13). Another described how his mother had had some concerns about him taking part in this study, because of the worry which discussing issues surrounding risk and predictive testing may cause (Q14). One relative described how her brother had been asked to take part in this study, but ignored the request; her mother had then approached her and encouraged her to participate (Q15). This relative suggested that it was her attitude towards health which set her apart from her brother.

Most relatives had not fully considered issues related to their personal susceptibility to RA prior to being approached to take part in this study (Q16). Some relatives indicated that taking part in this study had been a positive experience for them and had provided them with much needed knowledge, a chance for reflection on their risk and a greater understanding of RA and how it affected their sibling/parent (Q17). However, others described how they would prefer to avoid considering their personal risk of RA to avoid experiencing worry or anxiety about the future (Q18).

Perceptions surrounding the use of predictive tests: positive perspectives

Most relatives were in favour of the basic principle behind predictive testing—identifying those at risk and quantifying the level of risk (Q19). It was also felt that the information gained from predictive testing could be acted on to reduce the future risk of developing RA (Q20). In particular, relatives recognised the importance of early intervention, and they were aware that testing could put them ‘on alert’ for the early symptoms of RA (Q21) or suggested that they might be able to take preventive treatment (Q22). Many relatives felt that it was important to know that they were at risk and that

**Table 1** Details of first-degree relatives of patients with RA who participated in the interviews

Participant number	Gender	Age	Ethnicity	Relation to patient with RA	Experience of testing	Self-reported musculoskeletal symptoms	Interview country
Participant 1	Female	36	White British	Daughter	None	None	UK
Participant 2	Female	42	White British	Daughter	None	Previous septic arthritis	UK
Participant 3	Male	35	White British	Son	None	None	UK
Participant 4	Male	67	White British	Brother	None	None	UK
Participant 5	Male	31	White British	Son	Reports having had a 'genetic test' for RA (performed by family physician)	None	UK
Participant 6	Female	23	White British	Daughter	None	None	UK
Participant 7	Female	30	White British	Daughter	None	Ankle pain and intermittent ankle swelling attributed by patient to a previous 'ankle dislocation'	UK
Participant 8	Female	39	White British	Daughter	Rheumatoid factor previously measured	Elbow pain	UK
Participant 9	Female	54	White British	Sister	None	Finger pain	UK
Participant 10	Female	35	White British	Daughter	None	'Inflamed knee' during pregnancy	UK
Participant 11	Female	44	White British	Sister and daughter	None	Back pain	UK
Participant 12	Female	44	White British	Sister	None	Finger pain	UK
Participant 13	Female	41	White British	Sister and daughter	Rheumatoid factor previously measured by family physician	Finger pain, stiffness and swelling	UK
Participant 14	Female	60	White	Daughter	Has had 'blood tests' (participant unsure which)	Has a diagnosis of osteoarthritis	UK
Participant 15	Female	29	White British	Daughter	None	None	UK
Participant 16	Female	40	White British	Daughter	None	None	UK
Participant 17	Female	41	Asian (UK born)	Daughter	None	None	UK
Participant 18	Female	28	White British	Daughter	None	None	UK
Participant 19	Male	42	Chinese	Son	None	None	UK
Participant 20	Female	25	White British	Daughter	None	None	UK
Participant 21	Female	41	White British	Daughter	None	Had previous joint swelling in wrists and hands	UK
Participant 22	Female	32	White British	Sister	None	None	UK
Participant 23	Female	44	White British	Daughter	None	None	UK
Participant 24	Male	47	White British	Son	None	None	UK
Participant 25	Female	29	White German	Daughter	None	None	Germany
Participant 26	Female	37	White German	Daughter	None	None	Germany

Continued

Table 1 Continued

Participant number	Gender	Age	Ethnicity	Relation to patient with RA	Experience of testing	Self-reported musculoskeletal symptoms	Interview country
Participant 27	Female	51	White German	Daughter	None	None	Germany
Participant 28	Female	21	White Austrian	Daughter	None	None	Austria
Participant 29	Male	33	White Austrian	Son	None	None	Austria
Participant 30	Female	65	White Austrian	Sister	None	None	Austria
Participant 31	Female	36	White Austrian	Sister	Reports having had a blood test	None	Austria
Participant 32	Male	37	White Austrian	Son	None	None	Austria
Participant 33	Male	37	White Austrian	Son	None	None	Austria
Participant 34	Female	33	White Austrian	Daughter	None	None	Austria

RA, rheumatoid arthritis.

Table 2 Quotations related to an understanding of family history and genetic factors as risk factors for rheumatoid arthritis

Code	Quotation
Q1	I see that my mother has it and I'm just worried that it might be passed on to me or my sister or other members of my family. (Participant 19)
Q2	In my opinion it's environmental factors or genetics. (Participant 28)
Q3	So I know it's blood-related...I think if it was your cousin or your aunt there'd be a slim chance...being direct blood-related, I would class myself as, or think of myself that I am at a higher risk than most. (Participant 6)
Q4	I seem to follow my mum in absolutely everything, like my brother and sister they're quite like my dad, they never get ill, they never catch a cold. Whereas if there's a cold going around I will get it and the same with my mum...So I was a bit like 'oh, maybe I'll get it'. (Participant 18)
Q5	I know that there's a genetic tendency. That it runs in families. I'm female, so I'm more at risk because I'm female...I know first degree relative increases your risk, so yeah, it does worry me. (Participant 10)
Q6	Genetics really worry me because I don't know anything about them and I think when people think of genetics they think of like I don't know it's quite like a complicated thing that we're never going to understand because there's no simple way of putting it...But like your average Joe Bloggs [average person] isn't going to know extensive information about your genes. (Participant 20)
Q7	For me personally it's kind of hard facts and figures; I'm more comfortable knowing in terms of percentages. I know my dad has got rheumatoid arthritis, and if you've got a hard fact and figure to say that the chances of a close relative, son or daughter, developing rheumatoid arthritis at some point in their life then that information would be useful to me. (Participant 5)
Q8	It [life] wouldn't be predictable anymore; I wouldn't know how things would be from one day to the next, or in an hour's time, when I woke up the next morning, wondering what the day would bring. I think it's pretty serious, it restricts your everyday life. And it differs—my father has pain and sometimes it's there, sometimes it's not; it's unpredictable. (Participant 25)
Q9	I do worry about it, yeah, because I don't want to end up developing anything like that. I like to keep busy and I don't want to be restricted. It is a big worry, yeah. I don't want to go through what my mum's going through at the moment, because she's been through a lot. (Participant 13)
Q10	I've got pain down my left leg [okay], but I just don't know whether it's sciatica, or whether it could be something linked to arthritis, but I'm too frightened to go and have a scan. So I probably do need it to find that. I'm just putting it off. (Participant 15)

information related to their actual risk would be of value to them, allowing them to 'mentally' prepare for the future (Q23). Others could see the benefit of preparing for the functional limitations that may be associated with

RA (Q24). A few had already undertaken predictive testing to explore their personal risk of developing RA (Q25). Some were willing to be tested for altruistic reasons such as taking part in research (Q26).

**Table 3** Quotation related to personal considerations of rheumatoid arthritis risk and communication about risk within families

Code	Quotation
Q11	That's exactly what he doesn't talk to me about, he's the kind of person who leaves others out of it, deals with it by himself. (Participant 30)
Q12	I am worried about that...I was quite surprised when mum said that she'd had this letter explaining about the research that you're doing. (Participant 23)
Q13	He doesn't tend to talk about it. He didn't want to ask me to do this phone call, but forced himself to one day...This is probably the first time he's actually asked me to do anything and he was clearly uncomfortable. (Participant 24)
Q14	I never had that information of what happens, how you're made at higher risk, I've never had that in like black and white...which makes me think she doesn't know or maybe she's just trying to protect me like a mother does. Because I think she was quite worried about me taking part...she's quite worried about what I'd find out. (Participant 5)
Q15	My mum, sort of, mentioned this to him [brother], and he was just, like, ignored the fact that she'd said anything to me. And then she came to me and said, 'I thought I'd ask your brother first but he won't,' and I said, 'I don't mind,' but he's probably different to me, just blissful ignorance, whereas I'm probably a little bit different. (Participant 2)
Q16	Up until now I have never thought about it, what that would be like, whether it might happen. (Participant 28)
Q17	I guess before we spoke I couldn't understand what it was exactly that was making her finger sore or swollen or anything like that. I would just be like, drink more milk. (Participant 20)
Q18	You only worry too much and rack your brain, because then I have to consider that my children could get it too and then you would worry too much. It's more comfortable to avoid it. (Participant 32)

Table 4 Quotations related to perceptions surrounding the use of predictive tests: positive perspectives

Code	Quotation
Q19	I'm open to everything, well, I don't know why I shouldn't have that done, I couldn't think of a reason off the top of my head not to do it. (Participant 31)
Q20	If I was offered a test, I'd be very happy to have one. I don't need to think about that. Well, it might be if it might help me combat a disease later, or at least know how to treat it. Well, if I'm at risk I think it would be helpful to know. (Participant 3)
Q21	I would do that straight away, because I want to know as soon as possible, because I think the more you know the earlier, the more you can do about it. (Participant 31)
Q22	I think that with kind of information, I'd be more keen to, sort of, sort out what I needed to do to try and prevent that becoming a problem. If I could take some sort of medication to...head it off before it became a big problem. (Participant 2)
Q23	I think that would be a good thing. I think I'd like to know because then I may be able to prepare a bit more, like mentally as well. (Participant 20)
Q24	Yes, it would. I think I would have the test just to see what the long-term forecast is, because my job's fairly labour intensive. I'd be willing to know what the future holds, just from the point of view of my job circumstances at work. (Participant 19)
Q25	Actually I did get tested, but it was a long time ago. (Participant 27)
Q26	I'm not averse to having them, especially, if it helps with research and stuff like that. (Participant 2)

Perceptions surrounding the use of predictive tests: negative perspectives

The ability of predictive tests to quantify risk was widely discussed (Q27), with one participant questioning the specificity and sensitivity of the test (Q28). Relatives expressed a desire for tests that would, with a very high likelihood, be able to confirm or exclude the fact that they would develop RA (Q29). However, many relatives suspected that test results would give them an intermediate risk of developing RA and others highlighted concerns about 'false-positive' results (Q30). Some believed that predictive testing would not be able to give them answers to questions they thought were important, for example, how severe would their RA be were they to develop it, and when it would be most likely to begin (Q31).

Relatives were worried about the impact of testing on their family members and in particular on their sibling/parent with RA (Q32). Participants felt that seeking information about risk and pursuing testing would cause their relative with RA to experience stress, worry or feelings of guilt. Participants were further worried about the stress that predictive test results may cause them. One even suggested that such stress could cause the disease to develop earlier than it otherwise would (Q33).

Relatives felt that being given risk information when they were young would be a particular burden (Q34). Instead, they felt that testing should be left until later in life, when the chance of developing a condition like RA was higher. Risk information was considered to have significant implications for future life choices and could make them 'rush' through life (Q35). One relative

Table 5 Quotations related to perceptions surrounding the use of predictive tests: negative perspectives

Code	Quotation
Q27	Exactly, if it is only a vague presumption where they say, yes, you could perhaps out of two to five people or something, you could get it and the others wouldn't, well that is very vague. (Participant 32)
Q28	That depends on the test, how specified it is and how sensitive it is, otherwise I would not have the test done. (Participant 29)
Q29	Because if told me—it's only how likely, it's not a, 'You will develop it,' and it doesn't tell you when you will develop it. So I think if somebody said to me, 'There's this test out there and it'll tell you whether you might develop it,' I wouldn't want it, because you could just live your life in fear and never actually develop it. So unless it was 100% guaranteed, and somebody could say, 'You will develop it within this time frame,' I don't wanna [want to] spend the next 30 years worrying about something, when I could be enjoying those 30 years. So, no, I'd probably—it depends on the exact details of the test. (Participant 10)
Q30	Or, equally, I guess, false positive. If you've got one really bad, sort of, joint that you've tested, it could, kind of, put a bit of a negative spin on it. (Participant 1)
Q31	It would be nice to know when...at what point in time you were going to get ill, and how severe it was going to be... but I don't know whether a test can find that out. (Participant 25)
Q32	But I wouldn't want to worry my mum by saying, can you get me a leaflet on testing. I wouldn't want my mum to worry that I was going for this test...to know that if in five years time I'll get it, I don't want her to know that because I think that would worry her more than anything. (Participant 6)
Q33	On the one hand you know that you might develop the disease and it is of course stressful, because then you know, one day, when I'm about 30–40 years old, it will start and then my body will become weaker and I will get this disease, then it could create a lot of stress to have these negative thoughts. I don't know what the psychological effect would be on the body, whether it really might break out sooner. If you don't know, so, if you say, I don't know and you live each day as it comes, meaning that it might break out at a later date. (Participant 32)
Q34	From personal experience, I think it would be something that when I got a bit older and certain things started going wrong with me or I started getting more illnesses I'd think I'd need to start looking to what all these problems are. At this particular moment in time, when there's generally nothing wrong with me, I just think that I don't really need to delve too much into that sort of information. (Participant 4)
Q35	Yeah I kind of wouldn't want this test to tell me that I had a 50/50 chance of getting it in the next five years because that would change my entire perception on what I wanted. And I guess if someone gave me that bit of information I'd have to seriously think, well maybe I can't have that, maybe I've got to like push everything forward like get married and have kids before I start to take medication which I guess that's a lot of information I don't know about in that if I had to start taking that medication would that affect me having kids. It's like knowing when you're going to die that doesn't sit right with me either. (Participant 15)
Q36	I think, if, for argument's sake, I'd gone for the test tomorrow, and the results came back and they said, 'Yeah, you're at high risk,' and in two years' time, the symptoms kicked in, you're then thinking, 'Right, okay.' We'd probably want a second child and we'd want a third, 'Let's do it now,' sort of, thing, but otherwise, I think, you know, just life would carry on (Participant 6).
Q37	The GP [family physician] literally just sat me down, blurted some technical words out, medical terminology to me that went straight over my head and, again, didn't sink. I think, just keep simple, instead of baffling people with medical science, really, of your technical words that you use, compared to what, sort of, the general public are going to understand. (Participant 6)
Q38	I'd be happy, I think, if, before the test, someone would explain the kind of outcome to expect. And then when I got the test results back, it would be okay by post, as long as there was, kind of, accompanying information. I suppose at that point you'd probably end up going to see someone anyway to talk through what tablets or whatever you could take. (Participant 1)
Q39	I suppose it would be sensible to go and talk to somebody about it. (Participant 3)
Q40	I think it's a good idea to talk to somebody and find out more information. I think seeing somebody on a regular basis, like every year or something, might be good if you knew that you were going to get it. Obviously, you're going to have more and more questions, aren't you? Yeah, for an update and just to see how things are going. Obviously, as time goes on, you're going to have more questions and so I think it would be good to speak to somebody. (Participant 20)

suggested that such information could bring forward major life decisions, such as having children (Q36).

Some relatives reflected on previous negative personal experiences of having received poorly communicated test-related information (Q37). For some, the approach to the delivery of risk information represented an important feature of a predictive test and may determine

whether the test would be acceptable to them. Relatives discussed how they would want to be told prior to the test what format the result would take. Some suggested that they would like to receive the results by letter, and then be given the opportunity to discuss the results with a healthcare professional (Q38). Other relatives emphasised the importance of talking to someone about the



test result, especially to manage the psychological distress that may be associated with receiving a 'positive' test result (Q39). Many relatives felt that there was a need for ongoing support from a healthcare professional following testing (Q40).

DISCUSSION

This study explored the degree to which first-degree relatives of people with RA felt that they were susceptible to developing RA and their perceptions of predictive testing. Most relatives were aware that there was a genetic contribution to the risk of RA and that they may be susceptible to developing RA; however, they were unsure of the extent of the additional risk. Relatives highlighted the need for additional information about familial risk and described the need for better communication strategies in relation to imparting this information.

Generally, first-degree relatives felt that there was a need for more information and support specifically designed for the family members of people with RA. The current lack of support and information was suggested to have a number of effects, including family members not feeling able to communicate and support the person affected with RA and not feeling able to understand concepts surrounding the nature of RA and the risks associated with RA. Studies of information sharing among family members at risk of cancer have found that patients with the disease do not always communicate risk information in a timely or thorough fashion.⁴¹ Forrest *et al*⁴² found that relatives from smaller families, and female relatives, were more likely to make contact with genetic services. Research has shown that genetic counselling can facilitate interfamily communication and can help to minimise distress and increase the number of family members making contact with health services to be tested.^{43 44}

An incidental finding of this research was that being invited to take part in research about risk was the first time that some relatives had fully considered their personal susceptibility to RA. In some cases, this exposure was viewed positively, but in other cases, it caused worry and concern. It is difficult to draw conclusions about the specific impact taking part in this study had on relatives' well-being, but we note that relatives did indicate that support mechanisms would be helpful to enable them to understand and cope with risk-related information, especially if predictive testing were to be offered. We would suggest that researchers accessing participants in 'at-risk' populations pay particular attention to the impact that an invitation to participate and participation itself may have, and offer additional support to, mitigate against anxiety caused. While personal susceptibility may not have been considered, perceptions of RA severity may predict personal willingness to engage in predictive testing. It is possible that first-degree relatives of people with more severe forms of RA or poorly controlled

disease maybe more motivated to engage in predictive testing. This would be in line with the predictions of the health belief model.⁴⁵ A quantitative investigation to assess the effect of factors such as disease severity in people with RA, on their family members' perceptions of risk and orientation towards predictive testing, is needed to test this hypothesis.

In addition, it became apparent during the course of this study that some relatives were symptomatic but had not yet sought medical help. Detailed information on the health status of the participating relatives was not gathered within this study, but those who were symptomatic were advised to speak to their family physician and were given details of resources for obtaining additional information. However, the symptomatic nature of some relatives raises important issues surrounding informing relatives about risk, and the importance of seeking help quickly should symptoms emerge. While some relatives were aware that their symptoms may be indicative of the early stages of RA, and were worried about what information would be revealed to them if they sought help, few were aware of the importance of early intervention. Where information about the benefits of early intervention in preventing joint destruction made available to them, it is possible that their attitude to help-seeking may have been different.

This study has a number of limitations. First, our access to first-degree relatives was via patients with RA. Some relatives described how they were chosen in preference to other relatives, who would either worry too much or not be receptive to discussing issues related to risk. The findings presented may thus not fully reflect the range of views related to risk and testing held by first-degree relatives. This potential limitation highlights the need to fully understand the barriers that patients with RA face when discussing issues of risk with family members. A second limitation of this research was that the majority of participants were women. A criticism of many qualitative studies in the field of RA is that the male perspective is under-represented.⁸ While the female:male ratio of RA is typically 2:1, it is essential that studies attempt to include the views of more male participants. Therefore, we acknowledge that themes related to gender and male perspectives of risk and predictive testing did not reach saturation and are not represented in our data. A final limitation is that only a small number of individuals from ethnic-minority communities were interviewed; therefore, a full understanding of the cultural barriers to predictive testing was not achieved.

Besides these limitations, this study has a number of strengths. Relatives were sampled from centres in three different European countries and saturation of the main themes was achieved by combining interview data from all centres; furthermore, no differences in the views expressed by relatives sampled from different European countries were detected. Gathering data from multiple countries means that interventions developed based on

Box 2 Key messages

- ▶ Identifying those at risk of rheumatoid arthritis (RA), and quantifying their risk, may help guide targeted interventions to reduce future disease burden. This qualitative study found that first-degree relatives of people with RA, who are themselves at an enhanced risk of RA, had a number of concerns in relation to predictive testing.
- ▶ Some relatives would be unwilling to undergo predictive testing and were worried about the psychological impact of risk information. Others were more receptive and recognised that such information could facilitate the development and implementation of preventive strategies as well as encouraging prompt help-seeking and intervention at the onset of RA symptoms.
- ▶ Developing strategies that communicate risk information effectively while reducing the psychological burden associated with this information is essential.

these data are likely to be relevant in multiple contexts. A further strength of this study was the support given by an international panel of patient research partners who advised researchers and acted as coresearchers.

Identifying individuals at risk of RA may allow targeted interventions to reduce the risk and consequence of future disease; however, our data show that relatives have concerns about predictive testing and risk information that would result from it (the key messages of this study are summarised in [box 2](#)). The future development of strategies to quantify and communicate risk needs to take these views into account and incorporate approaches to mitigate concerns and minimise any negative psychological impact of risk information.

Author affiliations

¹Institute for Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK

²Division of Psychology, Nottingham Trent University, Nottingham, UK

³Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria

⁴University of Applied Sciences for Health Professionals, Upper Austria, Austria

⁵Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany

⁶Faculty of Medical and Human Sciences, School of Nursing, University of Manchester, Manchester, UK

⁷Centre for Research Ethics and Bioethics, Uppsala University, Uppsala, Sweden

⁸Department of Rheumatology, Sandwell & West Birmingham Hospitals NHS Trust, Birmingham, UK

Acknowledgements The authors thank the EuroTEAM Patient Research Partners Panel for their involvement in this research.

Contributors All authors made a substantial contribution to study conception and design. RJS, MS, ME, EM and KK collected the data. RJS analysed and interpreted data. All authors were involved in drafting the article, revised it and approved the final version of the article.

Funding This work was supported by European Union within the FP7 HEALTH programme under the grant agreement FP7-HEALTH-F2-2012-305549 (EuroTEAM) and by Riksbankens Jubileumsfond (The Swedish Foundation for Humanities and Social Sciences) under Grant M13-0260:1 'Mind the Risk'.

Competing interests None declared.

Ethics approval Ethical approval was obtained in the UK from the HumberBridge National Research Ethics Committee, in Austria from the Ethics Committee of the Medical University of Vienna and in Germany from the Ethics committee of the University of Erlangen-Nuremberg.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

REFERENCES

1. Symmons D, Turner G, Webb R, *et al*. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. *Rheumatology (Oxford)* 2002;41:793–800.
2. Lawrence RC, Helmick CG, Arnett FC, *et al*. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. *Arthritis Rheum* 1998;41:778–99.
3. Stack RJ, Shani M, Mallen CD, *et al*. Symptom complexes at the earliest phases of rheumatoid arthritis: a synthesis of the qualitative literature. *Arthritis Care Res* 2013;65:1916–26.
4. Stack RJ, van Tuyl LH, Sloots M, *et al*. Symptom complexes in patients with seropositive arthralgia and in patients newly diagnosed with rheumatoid arthritis: a qualitative exploration of symptom development. *Rheumatology (Oxford)* 2014;53:1646–53.
5. Chan KWA, Felson DT, Yood RA, *et al*. The lag time between onset of symptoms and diagnosis (Dx) of rheumatoid-arthritis (Ra) and its determinants. *Arthritis Rheum* 1992;35:S125.
6. Kiely P, Williams R, Walsh D, *et al*. Contemporary patterns of care and disease activity outcome in early rheumatoid arthritis: the ERAN cohort. *Rheumatology (Oxford)* 2009;48:57–60.
7. Nell VP, Machold KP, Eberl G, *et al*. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. *Rheumatology (Oxford)* 2004;43:906–14.
8. Stack RJ, Shaw K, Mallen C, *et al*. Delays in help seeking at the onset of the symptoms of rheumatoid arthritis: a systematic synthesis of qualitative literature. *Ann Rheum Dis* 2012;71:493–7.
9. Gerlag DM, Raza K, van Baarsen LG, *et al*. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. *Ann Rheum Dis* 2012;71:638–41.
10. Karlson EW, van Schaardenburg D, van der Helm-van Mil AH. Strategies to predict rheumatoid arthritis development in at-risk populations. *Rheumatology (Oxford)* 2016;55:6–15.
11. Raza K, Filer A. Predicting the development of RA in patients with early undifferentiated arthritis. *Best Pract Res Clin Rheumatol* 2009;23:25–36.
12. Yarwood A, Huizinga TW, Worthington J. The genetics of rheumatoid arthritis: risk and protection in different stages of the evolution of RA. *Rheumatology (Oxford)* 2016;55:199–209.
13. MacGregor AJ, Snieder H, Rigby AS, *et al*. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. *Arthritis Rheum* 2000;43:30–7.
14. Okada Y, Wu D, Trynka G, *et al*. Genetics of rheumatoid arthritis contributes to biology and drug discovery. *Nature* 2014;506:376–81.
15. Kim K, Bang SY, Lee HS, *et al*. High-density genotyping of immune loci in Koreans and Europeans identifies eight new rheumatoid arthritis risk loci. *Ann Rheum Dis* 2015;74:e13.
16. Somers EC, Antonsen S, Pedersen L, *et al*. Parental history of lupus and rheumatoid arthritis and risk in offspring in a nationwide cohort study: does sex matter? *Ann Rheum Dis* 2013;72:525–9.
17. Grant SF, Thorleifsson G, Frigge ML, *et al*. The inheritance of rheumatoid arthritis in Iceland. *Arthritis Rheum* 2001;44:2247–54.
18. Frisell T, Holmqvist M, Kallberg H, *et al*. Familial risks and heritability of rheumatoid arthritis: role of rheumatoid factor/anti-citrullinated protein antibody status, number and type of affected relatives, sex, and age. *Arthritis Rheum* 2013;65:2773–82.
19. Too CL, Muhamad NA, Ilar A, *et al*. Occupational exposure to textile dust increases the risk of rheumatoid arthritis: results from a Malaysian population-based case-control study. *Ann Rheum Dis* 2016;75:997–1002.



20. Qin B, Yang M, Fu H, *et al*. Body mass index and the risk of rheumatoid arthritis: a systematic review and dose-response meta-analysis. *Arthritis Res Ther* 2015;17:86.
21. Chou YY, Lai KL, Chen DY, *et al*. Rheumatoid arthritis risk associated with periodontitis exposure: a nationwide, population-based cohort study. *PLoS ONE* 2015;10:e0139693.
22. Orellana C, Saevarsdottir S, Klareskog L, *et al*. Postmenopausal hormone therapy and the risk of rheumatoid arthritis: results from the Swedish EIRA population-based case-control study. *Eur J Epidemiol* 2015;30:449–57.
23. Stoll T, Gordon C, Seifert B, *et al*. Consistency and validity of patient administered assessment of quality of life by the MOS SF-36; its association with disease activity and damage in patients with systemic lupus erythematosus. *J Rheumatol* 1997;24:1608–14.
24. Pattison DJ, Silman AJ, Goodson NJ, *et al*. Vitamin C and the risk of developing inflammatory polyarthritis: prospective nested case-control study. *Ann Rheum Dis* 2004;63:843–7.
25. Pattison DJ, Symmons DP, Lunt M, *et al*. Dietary risk factors for the development of inflammatory polyarthritis: evidence for a role of high level of red meat consumption. *Arthritis Rheum* 2004;50:3804–12.
26. Rosell M, Wesley AM, Rydin K, *et al*. Dietary fish and fish oil and the risk of rheumatoid arthritis. *Epidemiology* 2009;20:896–901.
27. Klareskog L, Stolt P, Lundberg K, *et al*. A new model for an etiology of rheumatoid arthritis: smoking May trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. *Arthritis Rheum* 2006;54:38–46.
28. Sparks JA, Chang SC, Liao KP, *et al*. Rheumatoid arthritis and mortality among women during 36 years of prospective follow-up: results from the Nurses' Health Study. *Arthritis Care Res (Hoboken)* 2016;68:753–62.
29. Sparks JA, Chen CY, Jiang X, *et al*. Improved performance of epidemiologic and genetic risk models for rheumatoid arthritis serologic phenotypes using family history. *Ann Rheum Dis* 2015;74:1522–9.
30. Aho K, Palosuo T, Raunio V, *et al*. When does rheumatoid disease start? *Arthritis Rheum* 1985;28:485–9.
31. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, *et al*. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. *Arthritis Rheum* 2003;48:2741–9.
32. Shi J, van de Stadt LA, Levarht EW, *et al*. Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. *Ann Rheum Dis* 2014;73:780–3.
33. de Hair MJ, van de Sande MG, Ramwadhoebe TH, *et al*. Features of the synovium of individuals at risk of developing rheumatoid arthritis: implications for understanding preclinical rheumatoid arthritis. *Ann Rheum Dis* 2014;66:513–22.
34. Gent YY, Voskuyl AE, Kloet RW, *et al*. Macrophage positron emission tomography imaging as a biomarker for preclinical rheumatoid arthritis: findings of a prospective pilot study. *Arthritis Rheum* 2012;64:62–6.
35. Ferucci ED, Darrah E, Smolik I, *et al*. Prevalence of anti-peptidylarginine deiminase type 4 antibodies in rheumatoid arthritis and unaffected first-degree relatives in indigenous North American Populations. *J Rheumatol* 2013;40:1523–8.
36. Sparks JA, Iversen MD, Miller Kroouze R, *et al*. Personalized Risk Estimator for Rheumatoid Arthritis (PRE-RA) Family Study: rationale and design for a randomized controlled trial evaluating rheumatoid arthritis risk education to first-degree relatives. *Contemp Clin Trials* 2014;39:145–57.
37. Novotny F, Haeny S, Hudelson P, *et al*. Primary prevention of rheumatoid arthritis: a qualitative study in a high-risk population. *Joint Bone Spine* 2013;80:673–4.
38. Bayliss K, Raza K, Simons G, *et al*. Perceptions of predictive testing for those at risk of developing a chronic inflammatory disease: a meta-synthesis of qualitative studies. *J Risk Res* 2016;2:1–23.
39. Falahee M, Simons G, Raza K, *et al*. Healthcare professionals' perceptions of risk in the context of genetic testing for the prediction of chronic disease: a qualitative metasynthesis. *J Risk Res* 2016;2:1–38.
40. Guest GS, MacQueen KM, Namey EE. *Applied thematic analysis*. Thousand Oaks, California: Sage Publications, 2012.
41. Forrest LE, Curnow L, Delatycki MB, *et al*. Health first, genetics second: exploring families' experiences of communicating genetic information. *Eur J Hum Genet* 2008;16:1329–35.
42. Forrest L, Delatycki M, Curnow L, *et al*. An audit of clinical service examining the uptake of genetic testing by at-risk family members. *Genet Med* 2012;14:122–8.
43. Forrest LE, Burke J, Bacic S, *et al*. Increased genetic counseling support improves communication of genetic information in families. *Genet Med* 2008;10:167–72.
44. Forrest LE, Delatycki MB, Skene L, *et al*. Communicating genetic information in families—a review of guidelines and position papers. *Eur J Hum Genet* 2007;15:612–18.
45. Rollins BL, Ramakrishnan S, Perri M. Direct-to-consumer advertising of predictive genetic tests: a health belief model based examination of consumer response. *Health Mark Q* 2014;31:263–78.

Perceptions of risk and predictive testing held by the first-degree relatives of patients with rheumatoid arthritis in England, Austria and Germany: a qualitative study

Rebecca J Stack, Michaela Stoffer, Mathias Englbrecht, Erika Mosor, Marie Falahee, Gwenda Simons, Josef Smolen, Georg Schett, Chris D Buckley, Kanta Kumar, Mats Hansson, Axel Hueber, Tanja Stamm and Karim Raza

BMJ Open 2016 6:
doi: 10.1136/bmjopen-2015-010555

Updated information and services can be found at:
<http://bmjopen.bmj.com/content/6/6/e010555>

These include:

References

This article cites 44 articles, 15 of which you can access for free at:
<http://bmjopen.bmj.com/content/6/6/e010555#BIBL>

Open Access

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

[Genetics and genomics](#) (96)
[Patient-centred medicine](#) (351)
[Qualitative research](#) (547)
[Rheumatology](#) (129)

Notes

To request permissions go to:
<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:
<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:
<http://group.bmj.com/subscribe/>